249 related articles for article (PubMed ID: 31550390)
1. Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes.
Zen Y; Chen YY; Jeng YM; Tsai HW; Yeh MM
Histopathology; 2020 Feb; 76(3):470-480. PubMed ID: 31550390
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint inhibitor-induced liver injury: A novel form of liver disease emerging in the era of cancer immunotherapy.
Zen Y; Yeh MM
Semin Diagn Pathol; 2019 Nov; 36(6):434-440. PubMed ID: 31358424
[TBL] [Abstract][Full Text] [Related]
3. Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review.
Onoyama T; Takeda Y; Yamashita T; Hamamoto W; Sakamoto Y; Koda H; Kawata S; Matsumoto K; Isomoto H
World J Gastroenterol; 2020 Jan; 26(3):353-365. PubMed ID: 31988594
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab-induced large duct cholangiopathy: Diagnosis and follow.up imaging.
Chatterjee A; Bivas BK; Gehani A; Sen S
J Postgrad Med; 2021; 67(1):43-45. PubMed ID: 33533751
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab-associated Hepatitis: Clinicopathologic Characterization in a Series of 11 Cases.
Johncilla M; Misdraji J; Pratt DS; Agoston AT; Lauwers GY; Srivastava A; Doyle LA
Am J Surg Pathol; 2015 Aug; 39(8):1075-84. PubMed ID: 26034866
[TBL] [Abstract][Full Text] [Related]
6. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
7. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury.
Zen Y; Yeh MM
Mod Pathol; 2018 Jun; 31(6):965-973. PubMed ID: 29403081
[TBL] [Abstract][Full Text] [Related]
8. Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report.
Nabeshima S; Yamasaki M; Matsumoto N; Takaki S; Nishi Y; Kawamoto K; Taniwaki M; Ohashi N; Hattori N
Cancer Treat Res Commun; 2021; 26():100270. PubMed ID: 33338849
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous occurrence of autoimmune pancreatitis and sclerosing cholangitis as immune-related adverse events of pembrolizumab.
Suda T; Kobayashi M; Kurokawa K; Matsushita E
BMJ Case Rep; 2021 Jun; 14(6):. PubMed ID: 34088696
[TBL] [Abstract][Full Text] [Related]
10. [Liver lesions induced by dihydralazine and propranolol].
Kunze KD; Porst H; Lohmann J; Tschöpel L
Zentralbl Allg Pathol; 1985; 130(1):19-29. PubMed ID: 3984541
[TBL] [Abstract][Full Text] [Related]
11. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer.
Kawakami H; Tanizaki J; Tanaka K; Haratani K; Hayashi H; Takeda M; Kamata K; Takenaka M; Kimura M; Chikugo T; Sato T; Kudo M; Ito A; Nakagawa K
Invest New Drugs; 2017 Aug; 35(4):529-536. PubMed ID: 28317087
[TBL] [Abstract][Full Text] [Related]
12. Delayed immune-related sclerosing cholangitis after discontinuation of pembrolizumab: A case report.
Tanaka T; Sakai A; Tsujimae M; Yamada Y; Kobayashi T; Masuda A; Kodama Y
World J Gastroenterol; 2022 Jul; 28(28):3732-3738. PubMed ID: 36161046
[TBL] [Abstract][Full Text] [Related]
13. Acute hepatitis E: a cause of lymphocytic destructive cholangitis.
Wendum D; Nachury M; Yver M; Lemann M; Fléjou JF; Janin A; Bertheau P
Hum Pathol; 2005 Apr; 36(4):436-8. PubMed ID: 15892007
[TBL] [Abstract][Full Text] [Related]
14. Antineutrophil cytoplasmic antibodies in chronic liver diseases: prevalence, titre, specificity and IgG subclass.
Bansi D; Chapman R; Fleming K
J Hepatol; 1996 May; 24(5):581-6. PubMed ID: 8773914
[TBL] [Abstract][Full Text] [Related]
15. Frequency and pathological characteristics of drug-induced liver injury in a tertiary medical center.
Ettel M; Gonzalez GA; Gera S; Eze O; Sigal S; Park JS; Xu R
Hum Pathol; 2017 Oct; 68():92-98. PubMed ID: 28873351
[TBL] [Abstract][Full Text] [Related]
16. Relationship between apoptosis, tumour necrosis factor, and cell proliferation in chronic cholestasis.
Floreani A; Guido M; Bortolami M; Della Zentil G; Venturi C; Pennelli N; Naccarato R
Dig Liver Dis; 2001 Oct; 33(7):570-5. PubMed ID: 11816546
[TBL] [Abstract][Full Text] [Related]
17. [A case of pembrolizumab-induced sclerosing cholangitis that was responsive to high-dose steroid therapy].
Nagasawa S; Miyazaki M; Morita Y; Tanaka K; Yada M; Masumoto A; Motomura K
Nihon Shokakibyo Gakkai Zasshi; 2021; 118(10):981-990. PubMed ID: 34629349
[TBL] [Abstract][Full Text] [Related]
18. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis.
Boberg KM; Fausa O; Haaland T; Holter E; Mellbye OJ; Spurkland A; Schrumpf E
Hepatology; 1996 Jun; 23(6):1369-76. PubMed ID: 8675153
[TBL] [Abstract][Full Text] [Related]
19. Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy.
Patil PA; Zhang X
Arch Pathol Lab Med; 2021 May; 145(5):571-582. PubMed ID: 32338534
[TBL] [Abstract][Full Text] [Related]
20. Hepatobiliary and Pancreatic: Biliary injury related to checkpoint inhibitor "pembrolizumab".
Kida A; Matsuda K; Matsuda M; Sakai A
J Gastroenterol Hepatol; 2019 Sep; 34(9):1478. PubMed ID: 31197882
[No Abstract] [Full Text] [Related]
[Next] [New Search]
